MENU ABOUT US MAKE A DONATION
The Epoch Times
Login
SEARCH
CLOSE
Help Center subscribe newsletter Newsstands Epoch Shop Gift
  • TOP NEWS
  • SPECIAL SERIES
  • SPECIAL COVERAGE
  • LATEST ARTICLES
  • US
    • US News
    • US Features
    • US Politics
    • US Crime News
    • New York
    • San Francisco
    • Los Angeles
  • Opinion
    • Thinking About China
    • Viewpoints
    • Unbridled Evil: The Corrupt Reign of Jiang Zemin in China
    • The Reader’s Turn
  • China News
    • US-China Relations
    • Chinese Regime
    • Business & Economy
    • Chinese Culture
    • China Human Rights
    • Social Issues
    • Organ Harvesting in China
  • World News
    • Africa News
    • Americas
    • Asia & Pacific
    • Canada
    • Europe
    • UK News
    • Australia News
    • International
    • Middle East
  • Business & Markets
    • Companies
    • Economy
    • Markets
    • Real Estate
    • Gold and Commodities
  • ARTS & CULTURE
    • Fine Arts & Craftsmanship
    • Performing Arts
    • Books
    • Traditional Culture
    • Shen Yun Special Coverage
    • Film & TV
  • Science
    • News
    • Space
    • Environment
  • Tech
    • Tech News
    • Tech Products & Reviews
    • Social Media
  • Sports
  • Videos
    • American Thought Leaders
    • China Insider
    • Crossroads
  • Bright
    • Lifestyle
    • Inspired
    • Family & Education
    • Personal Finance
    • American Essence
  • Entertainment
    • Film & TV
    • Entertainment News
  • Health
    • Experts
    • Conditions
    • Life & Wellness
  • Special Topics
    • Battlefields
SEARCH
  • EpochTV
  • US
  • US Politics
  • Opinion
  • World News
  • China
  • Hong Kong
  • Health
  • Bright
  • Arts
  • Falun Gong
  • Premium
  • Markets
  • Games
  • Livestream
  • More

Gilead

  • US Regulators Clear Remdesivir for COVID-19 Outpatient Use
    US Regulators Clear Remdesivir for COVID-19 Outpatient Use
    Some nonhospitalized patients seeking treatment for COVID-19 can now use the antiviral remdesivir after U.S. drug regulators on Jan. 21 expanded approval of the drug. The Food and Drug Administration ...
    January 22, 2022BY Zachary Stieber
  • FDA Approves First Treatment for COVID-19, Remdesivir
    FDA Approves First Treatment for COVID-19, Remdesivir
    The U.S. Food and Drug Administration on Thursday approved Gilead Sciences's antiviral drug remdesivir for the treatment of adults ...
    October 22, 2020BY Mimi Nguyen Ly
  • EU Buys Remdesivir to Treat 30,000 COVID Patients, Seeks More
    EU Buys Remdesivir to Treat 30,000 COVID Patients, Seeks More
    BRUSSELS—The European Union's executive said on Wednesday it had agreed to buy a limited supply of the COVID-19 ...
    July 29, 2020BY Reuters
  • Gilead’s $2,340 Price for Coronavirus Drug Draws Criticism
    Gilead’s $2,340 Price for Coronavirus Drug Draws Criticism
    The maker of a drug shown to shorten recovery time for severely ill COVID-19 patients says it will ...
    June 30, 2020BY The Associated Press
  • NIH Trial: Gilead’s Drug Works Best in COVID Patients on Oxygen
    NIH Trial: Gilead’s Drug Works Best in COVID Patients on Oxygen
    The U.S. National Institutes of Health (NIH) on Friday said that data from its trial of Gilead Sciences ...
    May 23, 2020BY Reuters
  • Remdesivir Explained—What Makes This Drug Work Against Viruses?
    Remdesivir Explained—What Makes This Drug Work Against Viruses?
    With the FDA approving Gilead’s Remdesivir as an emergency use treatment for the most acute cases of COVID-19, many people ...
    May 6, 2020BY The Conversation
  • 3,000 Participants Added to Trials for Experimental COVID-19 Treatment
    3,000 Participants Added to Trials for Experimental COVID-19 Treatment
    Gilead Sciences has increased the number of patients involved in two trials for its experimental COVID-19 treatment remdesivir. ...
    April 10, 2020BY Zachary Stieber
  • CCP Virus Patients Rush to Join Studies of Gilead Drug
    CCP Virus Patients Rush to Join Studies of Gilead Drug
    The new CCP virus made Dr. Jag Singh a patient at his own hospital. His alarm grew as ...
    April 6, 2020BY The Associated Press
  • How Much of Our Tax Money Goes to Big Pharma? A Lot.
    How Much of Our Tax Money Goes to Big Pharma? A Lot.
    After an 18 month investigation into the high cost of Gilead's hepatitis C drug Sovaldi—initially listed at $84,000 ...
    February 20, 2016BY Martha Rosenberg
  • Drug Maker Was Focused on Profits, Not Patients: Report
    Drug Maker Was Focused on Profits, Not Patients: Report
    WASHINGTON—The makers of a breakthrough hepatitis drug put profits before patients in pricing the $1,000 pill that's become ...
    December 1, 2015BY The Associated Press
TOP NEWS
  • NTD 8th International Piano Competition Winners Announced
    3hr By NTD Newsroom
    NTD 8th International Piano Competition Winners Announced
  • New PFAS Pesticides Are Entering Our Food System, Revealing a Conundrum
    4hr By Marina Zhang
    New PFAS Pesticides Are Entering Our Food System, Revealing a Conundrum
  • Kremlin Says Peace Talks Useful as US Envoys Leave Moscow for Kyiv
    4hr By Jacki Thrapp
    Kremlin Says Peace Talks Useful as US Envoys Leave Moscow for Kyiv
  • Labor Day Gas Prices Head for Record High
    5hr By Bill Pan
    Labor Day Gas Prices Head for Record High
  • Here’s What People Get Wrong About Modern Warfare | John Spencer
    9hr By Jan Jekielek, Epoch TV
    Here’s What People Get Wrong About Modern Warfare | John Spencer
  • State Department Says 75 Americans Remain Missing After Nepal-Tibet Flood
    9hr By Dorothy Li
    State Department Says 75 Americans Remain Missing After Nepal-Tibet Flood
  • US Forces Destroy 3 IRGC Oil Tankers After Iran Targets Navy Warships
    10hr By Jacki Thrapp
    US Forces Destroy 3 IRGC Oil Tankers After Iran Targets Navy Warships
  • Court Rules Pentagon Can Proceed With Firing Journalists
    11hr By Naveen Athrappully
    Court Rules Pentagon Can Proceed With Firing Journalists
  • Epoch Readers Divided Over Tariffs on Canada, United Over China Concerns
    12hr By Savannah Hulsey Pointer
    Epoch Readers Divided Over Tariffs on Canada, United Over China Concerns
  • Trump Grants Clemency to 30, White House Pardon Czar Says
    13hr By Kimberly Hayek
    Trump Grants Clemency to 30, White House Pardon Czar Says
The Epoch Times
Copyright © 2000 - 2026 The Epoch Times Association Inc. All Rights Reserved.
Back Top